Are you Dr. Borden?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 800-223-2273Fax+1 216-986-1191
Summary
- Dr. Ernest Borden, MD is an oncologist in Cleveland, Ohio. He is currently licensed to practice medicine in Ohio and North Carolina. He is affiliated with Cleveland Clinic and is a Dr. Ernest C. Borden at M.D. serves as Vice Chairman of Taussig Cancer Center. Dr. Borden serves as Director of the Center for Drug Discovery and Development of Taussig Cancer Center at Cleveland Clinic Foundation. He is a staff member in the Department of.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1970 - 1973
University of Pennsylvania Health SystemResidency, Internal Medicine, 1967 - 1968
Duke University HospitalInternship, Internal Medicine, 1966 - 1967
Duke University School of MedicineClass of 1966
Certifications & Licensure
NC State Medical License 1966 - 2022
OH State Medical License 1999 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Start of enrollment: 2004 Apr 01
- Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Start of enrollment: 2005 Jul 01
- S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma Start of enrollment: 2005 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 333 citationsOxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligandsXiaoxia Z. West, Nikolay L. Malinin, Alona Merkulova, Mira Tischenko, Bethany A. Kerr
Nature. 2010-10-21 - 231 citationsInterferons α and β in cancer: therapeutic opportunities from new insights.Ernest C. Borden
Nature Reviews. Drug Discovery. 2019-03-01 - 51 citationsInsights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.Paolo A. Ascierto, Bernard A. Fox, Walter J. Urba, Ana C. Anderson, Michael B. Atkins
Journal for Immunotherapy of Cancer. 2020-04-01
Grant Support
- SHP1 Targeted Inhibition By Stibogluconate For MelanomaNational Cancer Institute2007
- Phase I Evaluation Of Sodium StibogluiconateNational Center For Research Resources2006
- Shpi Targeted Inhibition By Stibogluconate For MelanomaNational Cancer Institute2006
- Clinical And Cellular Effects Of InterferonNational Center For Research Resources2004–2005
- Increasing Effects Of Interferons For MelanomaNational Cancer Institute2004–2005
- Clinical And Cellular Effects Of Interferon Alfa 1National Cancer Institute2004–2005
- Increasing Effects Of Interferons For MelanomaNational Cancer Institute2002–2003
- Clinical And Cellular Effects Of Interferon Alfa 1National Cancer Institute2001–2003
- Cancer And Leukemia Group BNational Cancer Institute1995–1997
- Phase 1a,1b Evaluation Of IL-6 In Patients With Advanced Malignant DiseaseNational Center For Research Resources1995
- Phase I/Ii--Clinical Evaluation Of Biological ResponseDivision Of Cancer Treatment1994
- Phase I/II - Clinical Evaluation Of Biological ResponseDivision Of Cancer Treatment1992–1993
- Physician Scientist Training In Cancer MedicineNational Cancer Institute1988–1990
- Oncology Education--Summer Research And PreventionNational Cancer Institute1988–1990
- Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1988–1990
- Phase IA And IB Trials Of Combinations Of InterferonDivision Of Cancer Treatment1985–1988
- Cancer Education ProgramNational Cancer Institute1987
- Clinical Evaluation Of Biological Response ModifiersDivision Of Cancer Treatment1985–1987
- Professional Oncology Education ProgramNational Cancer Institute1985–1986
Professional Memberships
- Member
